BL-1020 explained

BL-1020 (perphenazine 4-aminobutanoate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia. The chemical is an ester of GABA and perphenazine; pharmacologically it acts as a D2 antagonist and GABA agonist. It has shown pro-cognitive effects in the trials.[1] In March 2013, it went into the II/III trial phase.[2] It has been introduced by BioLineRx, a biopharmaceutical development company.

Notes and References

  1. Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M . Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study . The Journal of Clinical Psychiatry . 73 . 9 . e1168-74 . September 2012 . 23059159 . 10.4088/jcp.12m07642 .
  2. News: BioLineRx to Announce Interim Results of Phase II/III Trial for Schizophrenia Drug during week of March 18, 2013 . Biolinerx . Jan 7, 2013 . Biolinerx . dead . https://web.archive.org/web/20130303014709/http://www.biolinerx.com/default.asp?pageid=16&itemid=166 . 2013-03-03 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "BL-1020".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.